alvespimycin

Small moleculeexperimental

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) is a chemical compound which is a semi-synthetic derivative of the antibiotic geldanamycin. It is being studied for the possibility of treating cancer. — Wikipedia

Clinical trial activity

7 trials · 7 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2004 (NCT00088868)

Timeline

2000s

Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Jan 1, 2008
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Putative heat shock protein HSP 90-beta 2INHIBITOR
HSP90AB2P inhibitor
- Putative heat shock protein HSP 90-beta 2 (HSP90AB2P) ↗
Heat shock protein HSP90INHIBITOR
Heat shock protein HSP90 inhibitor
The anticancer mechanism is not fully elucidated. The primary mechanism may be the generation of ROS.
- Heat shock protein HSP 90-alpha (HSP90AA1) ↗
- Heat shock protein HSP 90-beta (HSP90AB1) ↗
- Heat shock protein HSP 90-alpha
- Heat shock protein HSP 90-beta
Unspecified targetOTHER
Reactive oxygen species
The anticancer mechanism is not fully elucidated. The primary mechanism may be the generation of ROS.

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O

Mol. weight: 616.76 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL383824 ↗
Wikipedia17-Dimethylaminoethylamino-17-demethoxygeldanamycin ↗
ChEMBLCHEMBL2105630 ↗

Also known as

17-desmethoxy-17-n,n-dimethylaminoethylamino-geldanamycin
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin
17-dimethylaminoethylamino-17-demethoxy-geldanamycin
17dmag
17-dmag
17-dmag
17-dmag
((4e,6z,8s,9s,10e,12s,13r,14s,16r)-19-(2-dimethylaminoethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo(16.3.1)docosa-4,6,10,18,21-pentaen-9-yl) carbamate
alvespimycin
alvespimycin
alvespimycin
alvespimycin
alvespimycin
alvespimycin hcl
alvespimycin hcl
alvespimycin hydrochloride
alvespimycin hydrochloride
alvespimycin hydrochloride
bms-826476
bms-826476
kos1022
kos 1022
kos-1022
nsc707545
nsc 707545

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01126502	Phase 1	May 1, 2010	National Cancer Institute (NCI), Ohio State University
NCT00780000	Phase 2	Apr 1, 2008	Bristol-Myers Squibb
NCT00803556	Phase 1	Jan 1, 2006	Bristol-Myers Squibb
NCT00248521	Phase 1	Oct 1, 2005	National Cancer Institute (NCI), University of London
NCT00089362	Phase 1	Jul 1, 2004	Cornell University, National Cancer Institute (NCI)
NCT00089271	Phase 1	Jul 1, 2004	National Cancer Institute (NCI), University of Pittsburgh
NCT00088868	Phase 1	Jun 1, 2004	National Cancer Institute (NCI), National Institutes of Health (NIH)

Showing 7 of 7 trials

Page 1 / 1

Organizations

Research & Development (7)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
National Cancer Institute (NCI)	Government	5	3	1	2004
Bristol-Myers Squibb	For profit	2	2	2	2006
Cornell University	Academic/Hospital	1	0	1	2004
National Institutes of Health (NIH)	Government	1	1	1	2004
Ohio State University	Academic/Hospital	1	0	1	2010
University of London	Academic/Hospital	1	1	1	2005
University of Pittsburgh	Academic/Hospital	1	0	1	2004

7 organizations

Page 1 / 1